Myotonic Dystrophy Drug Pipeline Landscape Report 2024 Featuring AMO Pharma, Harmony Biosciences, Entrada Therapeutics, Arrowhead Pharmaceuticals, Arthex Biotech, NeuBase Therapeutics, and Enzerna
01. März 2024 08:49 ET
|
Research and Markets
Dublin, March 01, 2024 (GLOBE NEWSWIRE) -- The "Myotonic Dystrophy - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "Myotonic Dystrophy- Pipeline...
Myotonic Dystrophy Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
15. Februar 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Myotonic Dystrophy Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight Myotonic...